Ceftriaxone and Jaundice in Neonates (CEFT)

University of Rochester

Status: Completed

Conditions: Jaundice and Sepsis in Neonates

Treatments: Drug: ceftriaxone

Study type: Observational

Funder types: Other

Identifiers

NCT03133637

29287

Details and patient eligibility

About

Ceftriaxone is an antibiotic often used for the management of sepsis. Neonates commonly have jaundice during the first postnatal week. Ceftriaxone will be given as standard of care for sepsis and investigators will observe the effect on jaundice.

Enrollment: 27 patients

Sex: All

Ages: 3 to 7 days old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Term infants with sepsis requiring IV antibiotics for more than 3 days and who has total serum bilirubin 6-12 mg/dL and resolving by day 4 of life.

Exclusion criteria

• Infants with asphyxia (Apgar score <3 at 5 minutes), chromosomal disorder, failed hearing test at baseline, family history of hearing loss, unconjugated hyperbilirubinemia requiring phototherapy, TORCH infection, craniofacial malformations, listeria monocytogenes infection, and any clinical conditions which will preclude discharge to home.

Trial design

27 participants in 1 patient group

Ceftriaxone Arm

Treatment:

Drug: ceftriaxone